CEO of Industry Standard Research Kevin Olson describes how marketers can take control of the ways in which they are evaluated. Services marketers are often not evaluated on actual marketing performance. The lack of objective and relevant performance measures can limit respect for the marketing function and influence within the organization, and that’s problematic. Instead, services … Continued
Editor Anna Rose Welch at Biosimilar Development discusses the role MSLs play in the pharma industry, and how it will evolve. Quite often in this industry, we refer to education as a singular initiative put together by one organization or a collaborative effort amongst several stakeholder organizations. Each biosimilar company is no doubt involved in putting … Continued
Editor Ed Miseta at Clinical Leader discusses CRA compensation and the CRA/RBM relationship. In 2015, risk-based monitoring (RBM) was making waves. That year Industry Standard Research (ISR) published an infographic which stated, “Increasingly sophisticated EDC capabilities, declining R&D productivity, and new regulatory guidance combined to create the ideal time to implement Risk-Based Monitoring.” Not everyone was … Continued
Chief Editor Louis Garguilo at Outsourced Pharma speaks with Industry Standard Research VP Kate Hammeke about how the newly released Biologic API Contract Manufacturer Quality Benchmarking (4th Edition) data bear on the concern about bioprocessing capacity shortage. Among the remaining responders to this question about a concern for bioprocessing capacity at CDMOs, 37% answered “Maybe.” … Continued
